Publication | Closed Access

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

VaccinationMelanomaImmunologyTumor ImmunityPathologyTherapeutic VaccineImmunotherapeuticsMalignant MelanomaVaccine DesignImmunological Adjuvant Qs-21ImmunotherapyMedicinePhase 1Tumor Microenvironment